Compiling observations and administration of Golden Sunrise Nutraceutical (Golden Sunrise) dietary supplement products should always be under the supervision of a licensed physicians, registered nurse, and medical specialists in the medical field.  Recommendations for Golden Sunrise products are based on the following criteria; Medical evaluation, assessment, diagnosis, monitoring, and medical report results of the patient.

1.0. CANCER CASE REPORTS

1.1. Patient with Pancreatic Cancer.

G.T. is a 71-year-old Hispanic male that was diagnosed with stage four pancreatic cancer on May 01, 2025.  Patient complained of lower back pain, was increasingly constipated, fatigued, and depressed from the diagnosis.  Patient heard of Golden Sunrise products for alternative Cancer Treatment through his family and set up an appointment with Oakview Medical Group.  Patient agreed to try it's Cancer Treatment and Sonja I. FONTANA (Mrs. Fontana) discussed his options and prescribed Cancer Treatment for him on May 17, 2025.  Results: Shortly after patient was taking Cancer Treatment, he could have a Bowel Movement (BM) and after this he steadily improved his BM to 3-times per day.  After a month patient's energy level noticeably improved, patient's health improved where he could walk outside, his depression no longer was an issue, his back pain which he claimed he suffered from for many years no longer was an issue, recovery continued and his health improved, mental clarity, and none of the previous issues were of note by this time.

AFTER CANCER TREATMENT FINDINGS: On July 21, 2025 MR Abdomen W/WO Contrast, MRI, and CT.  Pancreatic head mass as following:

                                                       Date            Pancreatic Ductal Dilation     Heterogeneous 

Before Cancer Treatment: May 01, 2025                    8-mm                           2.7 x 2.6-cm

After Cancer Treatment:    July 21, 2025                     5-mm                           2.5 x 1.4-cm    

• Liver; No significant abnormality.  Mildly enlarged measuring 19-cm in.
• Biliary; Mildly improved intrahepatic bile duct dilation in the left lobe.
• Pancreas; Mildly improved pancreatic ductal dilation in the body and tail, measuring up to 5-mm, previously 8-mm.  No significant peripancreatic inflammation/pancreatic is appreciated on current study.
• Spleen; No significant abnormality.  Borderline enlarged measuring 12-cm in CC.
• Kidneys/Ureters; No significant abnormality.  Simple bilateral renal cysts measuring up to 3.1-cm.  If present, simple renal cysts do not require imaging follow-up.
• Adenals; No visible adrenal lesion.
• Aorta and Vasculature; No significant atherosclerosis.  Re-demonstration of narrowed portal splenic confluence and splenic vein.
• Restroperitoneum; Multiple porta hepatitis and peripancreatic lymph nodes are seen, with a peripancreatic lymph node measuring 1.2-cm in short axis, image 48 series 8.  Portacaval lymph node short axis measures 1.1-cm, image 52 series 8.
• Bowel; No significant abnormality.  Re-demonstration of duodenal diverticulum.
• Mesentery/Peritoneum; No mass or ascites.
• Abdominal Wall; No significant abnormality.
• Bones; No significant abnormality.
• Lung Bases; Bilateral lung base patchy nodular hyperintense signals.  Lung bases not well assessed with MRI.

CONCLUSION: (1) Poorly defined mass at pancreatic head is difficult to delineate due to motion artifacts as described above, grossly stable.  The tumor is again abutting the SMV for 180 degrees.  No definite involvement of the SMA or portal vein definitively.  (2) Mildly improved pancreatic ductal dilatation in the body and tail and mildly improved intrahepatic bile duct dilatation in the left lobe, with suggestion of bile duct stent in place.  (3) Porta hepatis and peripancreatic lymphadenopathy.  (4) Bilateral lung base patchy nodular hyperintense signals, not well assessed with MRI.  Correlation with chest CT.

On July 21, 2025 MR Pelvis Male W/O Contrast.  Pancreatic head as following:

• Aorta/Iliac; No significant arterial abnormality for patient's age on limited evaluation.
• Bowel; No significant abnormality on limited evaluation.
• Mesentery/Peritoneum; No significant abnormality on limited evaluation.
• Abdominal Wall; No significant abnormality on limited evaluation.
• Bladder; No significant wall thickening or calculus.
• Pelvis Nodes; Bilateral obturator and external iliac chain lymph nodes, measuring up to 0.9-cm in short axis on the right, image 22 series 6.
• Pelvis Organs; No visible mass.
• Bones; L4-L5 degenerative disc disease.  No suspicious bony lesion identified....
• Other; Bilateral inguinal lymph nodes, measuring up to 1-cm in short axis...

CONCLUSION: (1) Bilateral inguinal lymph nodes, measuring up to 1-cm in short axis.  These are nonspecific and may be reactive.  (2) Bilateral obturator and external iliac chain lymph nodes, measuring up to 0.9-cm in short axis on the right.  These are nonspecific and may be reactive.  (3) No definitive metastatic disease in the pelvis.

1.2. Patient with Prostate Cancer.

C.S. is an 83-year-old white male that was diagnosed with prostate cancer on October 10, 2024.  Patient complained of an increase feeling tired all the time and had no energy function in day-to-day task.  After patient diagnosis he was asked to take chemotherapy treatment by his initial physician but refused.  Patient was looking for alternative therapies and wished to used herbal, botanical, or nutritional alternatives.  Patient heard Golden Sunrise dietary supplement products for alternative Cancer Treatment and consented to take alternative Cancer Treatment.  The Cancer Treatment was administered by Oakview Medical Group under supervision of Mrs. Fontana.  Results: After Cancer Treatment, patient again said he had more energy to do whatever he wanted and was very happy with the results from alternative Cancer Treatment.  Patient went to his oncologist for medical checkup as his prostate cancer on May 10, 2025.  The oncologist and received blood report results that showed patient improvement and did not move forward with any chemotherapy treatment and said to keep doing what you are doing.

AFTER CANCER TREATMENT FINDINGS: On September 08, 2025 Compute Tomography (CT) scan Abd and Pelvis W and W/O Contrast as following:

                                                          Date                      Prostate Specific Antigen (PSA) 

Before Cancer Treatment: October 10, 2024                    13-ng/mL                           

After Cancer Treatment:  November 05, 2024                9.6-ng/mL                            

• Osseous; No diffuse lytic or sclerotic process evident, no acute compression deformity of the lower thoracic or lumber region.
• Liver; No significant abnormality of the liver.
• Gallbladder; Cholelithiasis without cholecysitis.
• Pancreas; Fatty atrophy at least partially.
• Spleen; The spleen appears within normal limits.
• Adrenal Glands; Within normal limits.
• Kidney; Mild capsular calcifications on the left remain as do scattered begin kinay cysts on the right with the largest measuring 4.8-cm.  There is no hydronephyrosis or obstructing celculi.
• Aorta; Atherosclerotic changes are noted.  Nonancurysmal.
• Restroperitoneat; A small periaortic lymphy node is observed at the iliac bifurcation on the left.  This probably has not changed since the prior study.
• Bowel; There is no evidence for bowel obstruction.  No significant inflammatory changes appreciated.  No obvious mass lesion presnet.
• Appendix; No evidence for acute appendictis.
• Mesntery; No significant lymphadenopathy or evidence for significant mesenteric arterial stenosis to suggest chronic mesenteric ischemia.
• Abdominal Wall; Appears grossly unremarkable.
• Pelvis; Urinary bladder grossly unrevealing.  No enlarged pelvic sidewall lymphadenopathy or pelvic mass appreciated.  Prostate gland is noticeably diminished presumably treatment related.

IMPRESSION: Stable exam without convincing evidence for tumor recurrence on this study.  Begin-appearing stable right kidney cysts.

2.0. DIABETES CASE REPORT

2.1. Patient with Type 1 Diabetes.

N.O. is a 20-year-old white male that was diagnosed with Type 1 Diabetes on February; 2011.  Patient requires lifelong insulin injections daily to manage his blood glucose levels.  Patient's diet is restrictive though the patient rarely follows his diet regiment.  Patient started with Golden Sunrise Nutraceutical Metabolic Treatment (Metabolic Treatment) on May 10, 2019.  Results: After the patient was administered the Metabolic Treatment, the patient was then monitored by medical staff for a response.  After a short period of time the patient's blood glucose levels showed a significant decrease from 440-mg/dL to 60-mg/dL in less than two hours without the patient experiencing any symptoms such as dizziness, weakness, sweating, the patient did not demonstrate any adverse-effects, etc., and still carry on the usual daily activities.

AFTER METABOLIC TREATMENT FINDINGS: Blood sugar level as following:

                                                         Time              Blood Sugar Level  

Before Metabolic Treatment:  11:00 A.M.             440-mg/dL                          

After Metabolic Treatment:       1:00 P.M.                60-mg/dL         

3.0. MENOPAUSE CASE REPORT

3.1. Patient with Menopause.

S.T. is a 59-year-old white female that was diagnosed with Osteoporosis, Migraine Headaches, and Gastroesophageal Reflux Disease (GERD) in May; 2013.  Osteoporosis has been showing a steady degradation of bone density since its diagnoses which has increased other symptoms.  The patient is complaining of increased neck and back pain to the point of possible future immobility.  Patient started with Golden Sunrise Nutraceutical Metabolic Treatment (Metabolic Treatment) on July 18, 2017.  Results: After the Metabolic Treatment has overall dramatic results for pain that does not seem to have any real cause.  It also has an effect on patient nails and skin.  These changes were fairly quick.  Taking more time is the slight to moderate improvement in thumb arthritis, GERD symptoms, neck migraines, and migraines, foot pain.  Hip pain is reduced but patient most significant pain remaining.  Patient have a relatively steady more energy supply and do not feel hunger as much.  Sleep has been difficult, the first three-weeks patient didn’t sleep enough, but felt fairly good.  The last week patient have been sleeping more, but don’t feel rested.

AFTER METABOLIC TREATMENT FINDINGS: On June 26, 2018 Dual Femur Bone Density testing uses Dual-Energy X-Ray Absorptiometry (DEXA) scans as following:

                                                                          Densitometry Trend: Total Mean       

                                                           Date            Age (Years)    Bone Mineral Density (BMD)    Change vs Previous    Change vs Baseline    

Before Metabolic Treatment: July 05, 2017         58.5                         0.780-g/cm2                            --2.7%                           --6.3%             

After Metabolic Treatment:  June 26, 2018          59.5                         0.808-g/cm2                              3.6%                           --2.9%                   

                                                                           Densitometry Trend: L1-L4      

                                                           Date            Age (Years)    Bone Mineral Density (BMD)    Change vs Previous    Change vs Baseline    

Before Metabolic Treatment: July 05, 2017         58.5                         0.857-g/cm2                            --3.6%                           --6.2%             

After Metabolic Treatment:  June 26, 2018          59.5                         0.886-g/cm2                              3.4%                           --3.1%                   

• L1-L4 Lumbar Spine BMD: Technical Limitations; Mild degenerative disk disease and slerosis at L4-L5.
• Hip BMD: Technical Limitations: None.

IMPRESSION: (1) Osteoporosis.

                          (2) Lumbar spine bone density is not significantly changed from prior studies.  Hip bone density is significantly increased from Year-2017.

REFERENCES

[1] Tiêu Equation Experimentation of Understanding by Energy Transfer Quantum Mechanics https://www.scirp.org/journal/paperinformation?paperid=123783

[2] Particle Becomes Energy = Energy Becomes Mass https://globaljournals.org/GJSFR_Volume23/E-Journal_GJSFR_(A)_Vol_23_Issue_4.pdf

[3] Life Is Quantum Biology Effects Explained from the Schrödinger Equation, Serious or Life-Threatening Conditions or Diseases, and COVID-19 Results https://www.scirp.org/journal/paperinformation?paperid=120506

[4] Patient Quality-of-Life, Providers with Incentive Payments, Real-World  Evidence, and Reducing Healthcare Costs through New Innovations https://www.scirp.org/journal/paperinformation?paperid=124390

[5] The Nobel Prize - Otto Heinrich Warburg https://www.nobelprize.org/prizes/medicine/1931/warburg/biographical/

[6] Wikipedia - Otto Heinrich Warburg https://en.wikipedia.org/wiki/Otto_Heinrich_Warburg

[7] Huu S. TIEU’s Predicting Outcome of Severe Acute Respiratory Syndrome  (SARS) and Preparing the Treatment for COVID-19 (Coronavirus) and Other Viral Pandemics https://www.scirp.org/journal/paperinformation?paperid=123247

[8] Huu S. TIEU Request for FDA to Establish Regenerating Human Cells as Law on December 13, 2016 President Barack H. Obama Signed the 21st Century CURES Act into FDA Regulation and Law https://www.scirp.org/journal/paperinformation?paperid=122400